BioSpace News Archive

Biomedical Device Consultants and Laboratories (BDC Laboratories) introduced its Statys® GOA software today at MD&M West.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that findings from Patient-Reported Outcomes (PROs) of participants in the phase 2/3 QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) were published by the peer-reviewed journal Urology Practice.

Ainos, Inc. today announced that it has submitted the clinical hold complete response to the U.S. Food and Drug Administration (the “U.S. FDA”) for conducting a Phase II trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild COVID-19 symptoms.

Empower Clinic Services New Jersey LLC DBA Empower Pharma announced an agreement to purchase a facility in East Windsor, New Jersey from Eugia US Manufacturing LLC and enter into a contract manufacturing relationship.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer.

Singular Genomics Systems, Inc. announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology conference in Orlando, Florida.

ViiV Healthcare announced Dovato is now available in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no antiretroviral treatment history or to replace the current ARV regimen in those who are virologically suppressed on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.

PANTHERx® Rare is pleased to announce it was selected by Chiesi Global Rare Diseases, a business unit of the Chiesi Group, for the distribution of Filsuvez® topical gel, the first approved treatment for wounds associated with both dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

The Company intends to delist its common shares from Cboe Canada and is working to ensure that trading of its common shares on the CSE will commence immediately following such delisting, with an effective date to be disclosed in due course.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024.